新冠住院患者早期预防性抗凝与30天死亡率降低相关:美国队列研究
该回顾性队列研究纳入美国退伍军人事务部医疗系统2020年3月1日至7月31日收治的4297例实验室确诊SARS-CoV-2感染且无抗凝史的患者,比较入院24小时内启动预防性抗凝与未抗凝者的30天死亡率。逆概率加权分析显示,预防性抗凝组30天累积死亡率为14.3%,未抗凝组为18.7%,风险降低27%(HR 0.73,95%CI 0.66-0.81),且不增加需输血出血风险。
要点
- 新冠住院患者早期预防性抗凝与30天死亡风险降低27%相关(HR 0.73)。
- 预防性抗凝未增加需输血的出血风险(HR 0.87,95%CI 0.71-1.05)。
- 结果为支持入院时预防性抗凝作为初始治疗的指南推荐提供了真实世界证据。
核心结论
- 新冠住院患者早期启动预防性抗凝与30天死亡风险降低相关,且不增加严重出血风险。
研究设计与样本
- 观察性队列研究,纳入美国退伍军人事务部全国医疗系统2020年3月1日至7月31日收治的4297例实验室确诊SARS-CoV-2感染且无抗凝史的患者。
主要发现
- 4297例患者中3627例(84.4%)在入院24小时内接受预防性抗凝,其中超过99%(n=3600)使用皮下肝素或依诺肝素。
- 30天内共622例死亡,其中513例发生在预防性抗凝组;82%(510/622)的死亡发生在住院期间。
- 逆概率加权后,预防性抗凝组30天累积死亡率为14.3%(95%CI 13.1%-15.5%),未抗凝组为18.7%(95%CI 15.1%-22.9%)。
- 与未抗凝相比,预防性抗凝与30天死亡风险降低27%相关(HR 0.73,95%CI 0.66-0.81)。
- 预防性抗凝与需输血出血风险增加无关(HR 0.87,95%CI 0.71-1.05);定量偏倚分析e值下限95%CI为1.77。
临床怎么用
- 对于因新冠住院且无抗凝禁忌的患者,可考虑入院后早期启动预防性抗凝以降低30天死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether early initiation of prophylactic anticoagulation compared with no anticoagulation was associated with decreased risk of death among patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United States. DESIGN: Observational cohort study. SETTING: Nationwide cohort of patients receiving care in the Department of Veterans Affairs, a large integrated national healthcare system. PARTICIPANTS: All 4297 patients admitted to hospital from 1 March to 31 July 2020 with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and without a history of anticoagulation. MAIN OUTCOME MEASURES: The main outcome was 30 day mortality. Secondary outcomes were inpatient mortality, initiating therapeutic anticoagulation (a proxy for clinical deterioration, including thromboembolic events), and bleeding that required transfusion. RESULTS: Of 4297 patients admitted to hospital with covid-19, 3627 (84.4%) received prophylactic anticoagulation within 24 hours of admission. More than 99% (n=3600) of treated patients received subcutaneous heparin or enoxaparin. 622 deaths occurred within 30 days of hospital admission, 513 among those who received prophylactic anticoagulation. Most deaths (510/622, 82%) occurred during hospital stay. Using inverse probability of treatment weighted analyses, the cumulative incidence of mortality at 30 days was 14.3% (95% confidence interval 13.1% to 15.5%) among those who received prophylactic anticoagulation and 18.7% (15.1% to 22.9%) among those who did not. Compared with patients who did not receive prophylactic anticoagulation, those who did had a 27% decreased risk for 30 day mortality (hazard ratio 0.73, 95% confidence interval 0.66 to 0.81). Similar associations were found for inpatient mortality and initiation of therapeutic anticoagulation. Receipt of prophylactic anticoagulation was not associated with increased risk of bleeding that required transfusion (hazard ratio 0.87, 0.71 to 1.05). Quantitative bias analysis showed that results were robust to unmeasured confounding (e-value lower 95% confidence interval 1.77 for 30 day mortality). Results persisted in several sensitivity analyses. CONCLUSIONS: Early initiation of prophylactic anticoagulation compared with no anticoagulation among patients admitted to hospital with covid-19 was associated with a decreased risk of 30 day mortality and no increased risk of serious bleeding events. These findings provide strong real world evidence to support guidelines recommending the use of prophylactic anticoagulation as initial treatment for patients with covid-19 on hospital admission.
引用
- Rentsch CT, Beckman JA, Tomlinson L, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021. PMID: 33574135. doi:10.1136/bmj.n311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。